Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.81 |
| ▸ | HPGD | P15428 | 5/20 | 0.81 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.81 |
| ▸ | ALB | P02768 | 1/20 | 0.81 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.81 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.79 |
| ▸ | POLB | P06746 | 2/20 | 0.79 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.79 |
| ▸ | TUBB | P07437 | 2/20 | 0.79 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.79 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.79 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.79 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.79 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.79 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.79 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.79 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.79 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.79 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11195276 | 1.00 | KDM4E (0.81) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL10755857 | 0.94 | KDM4E (0.75) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL11076172 | 0.91 | AADAT (0.81) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL11198681 | 0.91 | KDM4E (0.85) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL26197440 | 0.91 | KDM4E (0.85) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL10406663 | 0.90 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL4545209 | 0.90 | KDM4E (0.84) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL11080941 | 0.90 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| SCHEMBL11112635 | 0.90 | KDM4E (0.77) | KDM4EALDH1A1HPGDHSD17B10ALB | |
| Nadifloxacin SCHEMBL4650640 | 0.89 | KDM4E (0.79) | KDM4EALDH1A1HPGDHSD17B10ALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3345594-A1 | SOLUBILIZED FLAVONOID COMPOSITION | Vizuri Health Sciences LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | VIZURI HEALTH SCIENCES CONSUMER HEALTHCARE, INC. | 2017-10-19 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-9730953-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | VIZURI HEALTH SCIENCES LLC (US) | 2017-08-15 | — | — | US | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | API GENESIS, LLC (US) | 2014-07-17 | — | — | US | disclosed |
| US-8637569-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds | API GENESIS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637569-B2 | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds | API GENESIS, LLC (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2012054090-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUNDS | API GENESIS, LLC (US) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199391-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | KDM4E 2079/4885ALDH1A1 1920/4885HPGD 244/4885 |
| US-20170296668-A1 | METHODS OF INCREASING SOLUBILITY OF POORLY SOLUBLE COMPOUNDS AND METHODS OF MAKING AND USING FORMULATIONS OF SUCH COMPOUND | ABCG2, CYP2F1, LSS | KDM4E 2079/4885ALDH1A1 1920/4885HPGD 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.